Parra Raul Jr.

MMSI CFO Parra buys 1,500 shares as stock trades well below highs; reverses pattern of five consecutive sales with buy conviction at depressed valuation.

Raul Parra Jr., the company's CFO, has reversed course sharply: after five consecutive sales of MMSI stock dating back to November 2024, he is now buying—a notable shift in insider behavior. The timing underscores conviction: the stock is trading well below its recent highs and has declined meaningfully over the past three months, creating a window where capital deployment carries real conviction rather than momentum. Parra's prior sales showed mixed timing—some well-timed exits that preceded declines, but others where the stock rose after his sales—suggesting he does not have a perfect track record reading MMSI's direction. That context makes the current buy more significant: he is purchasing at prices substantially lower than the recent peak, and the company itself remains profitable with solid revenue growth, providing a fundamental floor beneath the purchase. This is a credible signal of insider confidence in valuation, though not a guaranteed predictor given his mixed prior history in this exact stock.

CFO Parra sells 15,181 MMSI shares at $93.75; holds 24.2K shares post-trade; stock -15.8% from 52-week high.

Parra Raul Jr., as CFO and Treasurer, sold 15,181 shares worth $1,423,218.75, reducing his stake by 38.5% to 24.2K shares remaining. The sale occurred at $93.75, with the stock currently trading at $92.90 and down 15.8% from its 52-week high of $110.29, reflecting recent price weakness. His prior four sales at MMSI show mixed timing outcomes: one preceded a 90-day decline of 8.7%, but two others saw the stock rise 7.0% and 9.4% in the 90 days following the sale. The company's fundamentals remain solid with $355.4M quarterly revenue, $30.1M net income, and 7.9% annual growth, though the elevated P/E of 44.88 suggests current valuation is stretched relative to near-term earnings.

CFO Parra Raul Jr. sold 5,361 shares of MMSI at $103.58 on 2025-03-05, reducing holdings by 18.1%; stock down 7.8% from 52-week high.

Raul Parra Jr., CFO and Treasurer, sold 5,361 shares at $103.58, reducing his MMSI holdings from 29,562 to 24,201 shares. The sale occurred near the 52-week range with the stock currently at $101.73, down 7.8% from its $110.29 peak. His prior two measurable sales at MMSI (November 2024) both saw positive 90-day returns of +2.2% and +6.8% respectively, indicating those sales preceded stock appreciation rather than declines. The current price weakness and the magnitude of this reduction (18.1% of prior holdings) against a pattern of sales that have not preceded downturns warrant monitoring to determine whether this transaction signals a departure from that historical outcome.

MMSI CFO Parra sold 12,451 shares at $98.81 (Feb 28), cutting stake 34.0%; stock now $103.03, down 5.4% in 30 days.

Raul Parra Jr., CFO and Treasurer, liquidated 12,451 shares of MERIT MEDICAL SYSTEMS INC (MMSI) at $98.81 on 2025-02-28 for $1,230,283.31, reducing his holdings from 36,652 shares to 24,201 shares—a 34.0% reduction in stake. The stock has declined 5.4% over the subsequent 30 days and currently trades at $103.03, 6.6% below its 52-week high of $110.29. Examining Parra's prior sales at MMSI (Nov 2024): both were followed by positive 90-day returns (+2.2% and +6.8%), indicating the stock rose after those exits; neither sale proved well-timed by the sellside metric (0 of 2 prior sells were well-timed at 90 days). His broader cross-ticker track record shows 2 prior sells with an average 90-day return of +8.2% and a 90-day well-timed rate of 0.00%, again pointing to a pattern of selling into upside rather than before declines. Against fundamentals of $339.8M quarterly revenue, +7.9% annual growth, and a P/E of 41.54, this sale represents a material reduction by a chief financial officer at a mid-cap medical-device company, though the weak prior timing accuracy and recent stock weakness offer no clear predictive signal.

MMSI CFO Raul Parra Jr. sold 5,361 shares at $102.18 on 2024-11-07, reducing holdings by 24.7% to 16,361 shares ($547.8K)

Raul Parra Jr., CFO and Treasurer of Merit Medical Systems, executed a substantial sale reducing his stake from 21,722 to 16,361 shares—a 24.7% reduction in absolute holdings. The sale occurred at $102.18 per share just 2 days after a prior MMSI sell on 2024-11-05, suggesting consecutive exit activity. The stock currently trades at $104.24, near its 52-week high of $104.24, with strong recent momentum (+10.5% over 30 days, +15.4% over 90 days), suggesting the CFO sold ahead of or into appreciating valuation rather than into depressed conditions. Merit Medical's fundamentals show annual revenue growth of 9.2% and a P/E of 50.60, indicating a premium-priced profile. The consecutive sales pattern and concentration of selling activity in a narrow two-day window warrant attention to whether this reflects portfolio rebalancing or signaling around near-term visibility.

MMSI CFO Parra Jr. sold 29,646 shares (-64.4% of holdings) for $2.9M on 2024-11-05 at $98.02

Parra Raul Jr., CFO and Treasurer, executed a material reduction of his Merit Medical Systems stake, selling 29,646 shares at $98.02 for $2,905,900.92, representing a 64.4% reduction in his pre-transaction holdings from 46,007 shares to 16,361 shares. The sale occurred near the stock's 52-week high of $102.48, just 0.5% below the peak, at a point where the stock had gained 6.6% over the prior 30 days and 12.7% over 90 days. Notably, his same-ticker transaction history shows only this one measurable trade at MMSI following the reported sale on 2024-11-07, leaving limited precedent for evaluating whether his timing at this ticker aligns with broader market movements. The company's fundamentals show a P/E of 49.50 with annual revenue growth of 9.2% and net income of $28,444,000.00 on quarterly revenue of $339,845,000.00, suggesting a premium valuation relative to earnings growth. The substantial sale warrants analysis of whether this reflects broader capital allocation decisions or personal liquidity needs at the CFO level.